66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
39 citations
,
August 2022 in “Pharmaceutics” Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.
9 citations
,
February 2011 in “Biologics: Targets & Therapy” Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.
2 citations
,
February 2022 in “Journal of Pharmacy and Pharmacology” Methotrexate-loaded formulations showed promise for psoriasis treatment but need careful evaluation.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
February 2024 in “Australasian journal of dermatology” Janus kinase inhibitors may help treat lichen planopilaris.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
9 citations
,
October 2012 in “Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology” Stopping the drug olanzapine can reverse hair loss caused by it.
May 2022 in “Indian Journal of Pharmacology” Sodium valproate can cause serious high blood pressure in children.
155 citations
,
June 2009 in “International Journal of Dermatology” Lichen planus is a skin condition that can resolve on its own, is linked to hepatitis C, and increases the risk of skin cancer.
April 2023 in “Dermatology practical & conceptual” Lenalidomide helps hair follicle stem cells turn into melanocytes, which may improve repigmentation in vitiligo.
10 citations
,
October 2017 in “Pediatric neurology” Biotin and acetazolamide improved hair and nail growth, mental function, and reduced headaches in a child with autism.
3 citations
,
April 2002 in “The American Journal of Medicine” The document concludes that early diagnosis of Balint's syndrome is crucial for effective treatment and that understanding drug interactions, like between ritonavir and statins, is important for patient care.
Tjalma Syndrome is a rare condition in people with lupus, causing fluid buildup and high CA-125 levels, but not due to tumors.
January 2024 in “Clinical and Experimental Dermatology” Baricitinib helps treat severe hair loss in people over 65.
2 citations
,
November 1990 in “International Journal of Dermatology” Albendazole can cause hair loss, and piroxicam can cause fixed drug eruption.
25 citations
,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
January 2024 in “Dermatologic Therapy” Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.
2 citations
,
May 2021 in “Clinical Pharmacology in Drug Development” Clascoterone is safe for the heart, even at high doses.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral Janus kinase inhibitors may be an effective treatment option for lichen planopilaris with some risk of increased cholesterol and liver enzyme levels.
June 2021 in “Research Square (Research Square)” Sudanese epilepsy patients often experience hair loss from anti-epileptic drugs but continue their medication regardless of cosmetic side effects.
8 citations
,
July 2020 in “Medicine” Helmet-like device safely increases hair density for people with hair loss.
143 citations
,
May 2002 in “PubMed” LGD1069 effectively prevents breast tumors in mice without toxicity.